N/A
Completed N=561
Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation
Source: ClinicalTrials.gov NCT01707368 ↗Enrolled (actual)
561
Serious AEs
0.5%
Results posted
Sep 2018
Primary outcomePrimary: The Course of Disease and Relapse Management During Treatment With Daivobet® Gel Under Consideration of Patient's Individual Application Habits Under Daily Use Conditions. — 277; 121; 59; 24 Participants
Summary
The purpose of this observational study is to document the course of disease and relapse management during treatment with Daivobet® Gel under consideration of patient's individual application habits under daily use conditions.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Course of Disease and Relapse Management During Treatment With Daivobet® Gel Under Consideration of Patient's Individual Application Habits Under Daily Use Conditions. |
277; 121; 59; 24; 48 | — |
| SECONDARY PGA (Physician's Global Assessment of Psoriasis Vulgaris Severity) |
66; 177; 153; 115; 16; 1 | — |
| SECONDARY Side Effects |
0; 0; 2; 1; 8; 5 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with light to moderate psoriasis vulgaris of trunk and extremities and treatment with Daivobet® Gel was planned anyway.
- Minimum of 3 years diagnosed psoriasis vulgaris.
Exclusion Criteria
- Previous therapy with Daivobet® Gel
- Systemic therapy of psoriasis vulgaris
- Contraindications of Daivobet® Gel in the German package insert
- people that are incapable to give free consent
Data sourced from ClinicalTrials.gov (NCT01707368). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.